创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

袁家佳, 薛冉, 王小娟, 许凌霄, 沈琳, 周军. 胆道系统肿瘤药物治疗的临床问题和进展[J]. 药学进展, 2021, 45(1): 14-26.
引用本文: 袁家佳, 薛冉, 王小娟, 许凌霄, 沈琳, 周军. 胆道系统肿瘤药物治疗的临床问题和进展[J]. 药学进展, 2021, 45(1): 14-26.
YUAN Jiajia, XUE Ran, WANG Xiaojuan, XU Lingxiao, SHEN Lin, ZHOU Jun. Clinical Problems and Progress in Pharmacotherapy for Biliary Tract Carcinoma[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 14-26.
Citation: YUAN Jiajia, XUE Ran, WANG Xiaojuan, XU Lingxiao, SHEN Lin, ZHOU Jun. Clinical Problems and Progress in Pharmacotherapy for Biliary Tract Carcinoma[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 14-26.

胆道系统肿瘤药物治疗的临床问题和进展

Clinical Problems and Progress in Pharmacotherapy for Biliary Tract Carcinoma

  • 摘要: 目前,胆道系统肿瘤的全球发病率呈上升趋势,现有系统疗法主要为化学治疗,但临床疗效极为有限,主要归因于其基因组,表观遗传和分子水平上的高度异质性。而靶向治疗和免疫治疗的出现,为胆道系统肿瘤的治疗开辟了新路径。在过去的几年里,人们对胆道系统肿瘤的复杂性进行了深入的探索,并开发了可能有助于改善患者预后的新型疗法。通过对目前胆道系统肿瘤领域的最新研究进展进行综述,以期进一步指导临床实践。

     

    Abstract: Nowadays, the global occurrence of biliary tract carcinoma is on the rise. The current systemic treatment is mainly chemotherapy, but the clinical efficacy is extremely limited, mainly due to its high degree of heterogeneity at the genomic, epigenetic and molecular levels. The emergence of targeting therapy and immunotherapy has opened up a new channel for the treatment of biliary tract carcinoma. In the past years, in-depth exploration of the complexity of biliary tract carcinoma has been conducted and new therapies that may help improve the prognosis of patients have been developed. This paper reviews the latest research progress in the field of biliary tract carcinoma, in the hope of providing further guidance for clinical practice.

     

/

返回文章
返回